Researchers are working to refine a cell-based assay that more accurately identifies antibodies for myelin oligodendrocyte glycoprotein (MOG) in the serum of patients with neuromyelitis optica spectrum disorders. Some think that anti-MOG-positive patients may even represent a distinct demyelinating disease.

Phase 3 results show that daclizumab reduces disease activity in relapsing-remitting multiple sclerosis by half compared with interferon, as measured by brain imaging, with skin and other side effects. The drug works in surprising ways that are revealing new details about the pathogenesis of MS.